Norwegian version of this page

Colorectal Surgery

The research group conducts clinical and molecular genetic (tumor, blood and faeces) studies on colorectal cancer (crc).

About the Group

The colorectal surgery group engages in both clinical and molecular-translational research. The main aims for the translational projects are detection and validation of new diagnostic, prognostic, predictive and monitoring molecular biomarkers, and to make them feasible in the routine clinical setting across laboratories. This effort focuses on achieving a more personalized treatment of patients.

The Group Studies

  • Primary tumor colon - rectum (crc)

  • Early cancer in the rectum

  • Liver Metastases

  • Liquid biopsy at crc

  • Oncological treatment of colorectal cancer

  • Tumor cells in circulation and bone marrow

  • Cultivation / drug testing on living cancer cells

Innovation as a tool towards advanced treatment possibilities, is an important part of the group's effort and several patents have been registered by the group during the past years.

Project Teams

The colorectal surgery research group covers a broad range of topics and consists of two sub-teams.

Clinical Studies

  • Clinical studies on colorectal cancer

    • Survival, prognostic factors, complications to surgery

  • Transanal endoscopic microsurgery (TEM) for localization of large polyps and early rectum cancer

    • Complications. Survival.We have regional function for this patient Group

  • Together with geriatricians (Ass. Prof. Siri Rostoft)

    • Broad geriatric assessment to assess operational risk in the elderly. Completed Phd Siri Rostoft

    • Broad geriatric assessment to identify patients at risk of postoperative complications and investigate whether preoperative interventions give a benefit to these patients. RCT, PhD project, fellow Nina Ommundsen

    • GoSafe - study, multinational, multicenter - functional pre-postoperative function in elderly patients

  • Together with health economists (Ass Prof. Eline Aas)

    • Model to estimate the cost and survival of colorectal cancer. Completed PhD project - Pål Joranger

  • Together with radiologist (General Ellen Viktil)

    • MR staging of rectal polyps and early cancer



  • Molecular Genetics Dept of Molecular Oncology, OUH

    • Prof. Ragnhild A Lothe

    • Ass. Prof Anita Sveen

    • Prof. Rolf I Skotheim

    • Prof. Guro E Lind

  • Large-scale genome analyzes (ploydi), Håvard Danielsen, Dept. Medical Informatics

  • Pathology, Aud Svindland, Else Marit Løberg, Frode Jahnsen

  • Oncology, Kjell Magne Tveit, Marianne Grønlie Guren, Tormod Kyrre Guren, Olav Dajani

  • Liver Surgery, Bjørn Atle Bjørnbeth, Bård Røsok, Kristoffer Watten Brudvik

  • Radiology, Andreas Abildgaard, Vanja Cengija, Ellen Viktil


  • Rodrigo Dienstmann PI, Oncology Data Science (ODysSey) Group, Vall D’Hebron Institute of oncology, Barcelona, Spain
  • Research Scientist, Computational Oncology Group, Sage Bionetworks
  • Justin Guinney, Vice President, Computational Oncology group at Sage Bionetworks 
  • European Society of Coloproctology collaborating group.

Selected Publications


  • Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2020) Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.  Mol Oncol 2020 Dec  Online ahead of print PMID 33325154

  • Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer ESMO Open, 2020; 5 (6), e001040

  • Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityEBioMedicine, 2020; 59, 102923

  • Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020) Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity Clin Cancer Res, 2020; 26 (15), 4107-4119

  • Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liestøl K, Maddison J, Askautrud HA, Pradhan M, Nesheim JA, Albregtsen F, Farstad IN, Domingo E, Church DN, Nesbakken A, Shepherd NA, Tomlinson I, Kerr R, Novelli M, Kerr DJ, Danielsen HE (2020) Deep learning for prediction of colorectal cancer outcome: a discovery and validation study Lancet, 2020; 395 (10221), 350-360

  • 2015 European Society of Coloproctology Collaborating Group.   Predictors for Anastomotic Leak, Postoperative Complications, and Mortality After Right Colectomy for Cancer: Results From an International Snapshot Audit. Dis Colon Rectum. 2020 May;63(5)

  • Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clin Colorectal Cancer. 2020 Mar;19(1):e26-e47

  • Joranger P, Nesbakken A, Sorbye H, Hoff G, Oshaug A, Aas E. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. Eur J Health Econ. 2020 Apr;21(3):321-334

  • Eilertsen IA, Moosavi SH, Strømme JM, Nesbakken A, Johannessen B, Lothe RA, Sveen A Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 2020 Jan 28;469:246-255. 

  • Lopes N, Bergsland CH, Bjørnslett M, Pellinen T, Svindland A, Nesbakken A, Almeida R, Lothe RA, David L, Bruun J   Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.Lab Invest. 2020 Jan;100(1):120-134

G. Wiedswang

  • Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H (2020) Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen Mol Oncol

  • Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Bendigtsen Schirmer C, Renolen A, Borgen E, Naume B, Wiedswang G (2020) Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information BMC Cancer, 20 (1), 1107

  • Bärebring L, Kværner AS, Skotnes M, Henriksen HB, Skjetne AJ, Henriksen C, Ræder H, Paur I, Bøhn SK, Wiedswang G, Smeland S, Blomhoff R (2020) Use of bioelectrical impedance analysis to monitor changes in fat-free mass during recovery from colorectal cancer- a validation study Clin Nutr ESPEN, 40, 201-207

  • Kværner AS, Harnæs H, Alavi DH, Bärebring L, Henriksen HB, Guren MG, Lauritzen PM, Eggesbø HB, Wiedswang G, Smeland S, Blomhoff R (2020) Should calculation of chemotherapy dosage for bowel cancer be based on body composition? Tidsskr Nor Laegeforen, 140 (8)

  • Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G (2020) Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma Ann Surg, 271 (3), 549-558

T. Glomsaker

  • Tønnesen CJ, Young J, Glomsaker T, Mala T, Løberg M, Bretthauer M, Refsum E, Aabakken L (2020).  Laparoscopy-assisted versus balloon enteroscopy-assisted ERCP after Roux-en-Y gastric bypass  Endoscopy, 52 (8), 654-661

Published Aug. 7, 2014 3:05 PM - Last modified June 25, 2021 2:49 PM


Group leader

  • Ole Helmer Sjo 


  • Morten Tandberg Eriksen
  • Arild Nesbakken
  • Gro Wiedswang
  • Ingeborg F. Backe
  • Lars Thomas Seeberg
  • Tom Glomsaker
  • Tom-Andreas Wik
  • Tuva Høst Brunsell
Detailed list of participants